Acurable, a UK-based medical device company, announced it raised €11 million ($10.8 million) in a Series A funding round led by Kibo Ventures.
Mundi Ventures, Comprador Holdings and Kindred Capital participated in the raise.
The company will use the funds to accelerate the international expansion of its first home sleep testing device, the AcuPebble SA100, which enables users to detect and monitor obstructive sleep apnea.
Acurable will also develop new products for chronic obstructive pulmonary disease (COPD), asthma and cardiovascular conditions.
The AcuPebble SA100 was launched in the UK and Spain in 2021. The company is looking to scale within the two countries and expand in Europe and North America.
The device received a CE mark in Europe for the automated diagnosis of OSA at home. Last year, it received FDA 510(k) clearance in the U.S. to sense, record and interpret physiological signals, like a patient’s respiratory pattern, while they sleep to prescreen for OSA.
Several companies provide at-home sleep apnea diagnostic testing offerings, including Israeli-based Itamar Medical, which broadened the capabilities of its at-home sleep apnea diagnostic testing line in 2021.
Its WatchPAT system attaches to a user’s index finger, chest and wrist, measuring and recording peripheral arterial (PAT) signal, heart rate, oximetry, actigraphy, body position, snoring and chest motion to identify events of sleep apnea.
In 2021, it expanded its capabilities with SleePath, allowing users to document subjective data from its test directly into the connected app, providing physicians a fuller picture via self-reports and sleep study metrics.
In 2020, ResApp launched SleepCheck, an at-home sleep apnea screening app, and that same year French firm Withings released Sleep Analyzer, an under-the-mattress sleep-tracking mat that can be used to detect sleep apnea.